Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T-AXL-IRDye800CW is an AXL-targeted near-infrared-II (NIR-II) fluorescent probe developed for the non-invasive diagnosis and precision surgical navigation of colorectal cancer (CRC). It is constructed by conjugating the near-infrared fluorescent dye IRDye800CW to an AXL-specific antibody. The probe specifically binds to AXL, a transmembrane receptor overexpressed in colorectal cancer that is associated with tumor invasion and metastasis. In preclinical models, T-AXL-IRDye800CW demonstrates high tumor specificity and affinity, enabling the visualization of primary tumors and small mesenteric metastases (< 1 mm) under NIR-II imaging guidance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on T-AXL-IRDye800CW.